[go: up one dir, main page]

DK1372608T3 - Medicinske aerosolformuleringer - Google Patents

Medicinske aerosolformuleringer

Info

Publication number
DK1372608T3
DK1372608T3 DK02701145T DK02701145T DK1372608T3 DK 1372608 T3 DK1372608 T3 DK 1372608T3 DK 02701145 T DK02701145 T DK 02701145T DK 02701145 T DK02701145 T DK 02701145T DK 1372608 T3 DK1372608 T3 DK 1372608T3
Authority
DK
Denmark
Prior art keywords
aerosol formulations
salts
medical aerosol
medical
dosing
Prior art date
Application number
DK02701145T
Other languages
English (en)
Inventor
Rudi Mueller-Walz
Carsten Niederlaender
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Application granted granted Critical
Publication of DK1372608T3 publication Critical patent/DK1372608T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK02701145T 2001-03-30 2002-03-11 Medicinske aerosolformuleringer DK1372608T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH6012001 2001-03-30
CH15272001 2001-08-20
PCT/CH2002/000145 WO2002078671A1 (de) 2001-03-30 2002-03-11 Medizinische aerosolformulierungen

Publications (1)

Publication Number Publication Date
DK1372608T3 true DK1372608T3 (da) 2007-12-27

Family

ID=25737693

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02701145T DK1372608T3 (da) 2001-03-30 2002-03-11 Medicinske aerosolformuleringer

Country Status (22)

Country Link
US (1) US20040101483A1 (da)
EP (1) EP1372608B1 (da)
JP (1) JP4824267B2 (da)
CN (1) CN100496608C (da)
AT (1) ATE375142T1 (da)
AU (1) AU2002234476B2 (da)
CA (1) CA2442415C (da)
CY (1) CY1107128T1 (da)
CZ (1) CZ301676B6 (da)
DE (1) DE50211045D1 (da)
DK (1) DK1372608T3 (da)
ES (1) ES2292713T3 (da)
HU (1) HU229798B1 (da)
NO (1) NO332848B1 (da)
NZ (1) NZ528640A (da)
PL (1) PL207377B1 (da)
PT (1) PT1372608E (da)
RO (1) RO121172B1 (da)
RU (1) RU2294737C2 (da)
SK (1) SK286394B6 (da)
WO (1) WO2002078671A1 (da)
ZA (1) ZA200307161B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
WO2003024396A2 (en) 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
PT1572622E (pt) * 2002-12-10 2006-08-31 Sepracor Inc Sal de levalbuterol
EP1646370A1 (en) * 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
GB0316335D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
DE602005007708D1 (de) * 2004-02-06 2008-08-07 Meda Pharma Gmbh & Co Kg Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen
PT1713473E (pt) 2004-02-06 2013-05-13 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd
WO2005074982A2 (en) 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
ES2570332T3 (es) 2005-03-16 2016-05-17 Meda Pharma Gmbh & Co Kg La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias
CA2627982C (en) 2005-11-10 2013-09-10 Nicholas S. Bodor Soft anticholinergic esters
NZ568349A (en) 2005-12-21 2011-05-27 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
AU2012200449B2 (en) * 2005-12-21 2013-07-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB0602897D0 (en) * 2006-02-13 2006-03-22 Jagotec Ag Improvements In Or Relating To Dry Powder Inhaler Devices
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
GB0625303D0 (en) * 2006-12-19 2007-01-24 Jagotec Ag Improvements in and relating to metered dose inhalers
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI792140B (zh) * 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
AU2015201864A1 (en) * 2009-05-29 2015-04-30 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
ES2467928T3 (es) * 2009-12-23 2014-06-13 Chiesi Farmaceutici S.P.A. Formulación en aerosol para EPOC
CA2785321C (en) 2009-12-23 2018-08-21 Chiesi Farmaceutici S.P.A. Combination therapy for copd
MX340264B (es) * 2009-12-23 2016-07-04 Chiesi Farm Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica.
JP5513177B2 (ja) * 2010-03-08 2014-06-04 共同印刷株式会社 湿度インジケータとその製造方法、該製造方法に用いる湿度インジケータ用塗料
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
CN103874483B (zh) * 2011-10-11 2017-09-12 奇斯药制品公司 包衣了脂肪酸的β‑激动剂的晶体微粒
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
CN109069390A (zh) * 2016-04-11 2018-12-21 苏文生命科学有限公司 格隆溴铵的外用喷雾制剂

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1096357A (en) * 1965-02-11 1967-12-29 Fisons Pharmaceuticals Ltd Aerosol compositions
JPS55361B1 (da) * 1970-09-17 1980-01-08
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
EP0561166A1 (de) * 1992-03-17 1993-09-22 ASTA Medica Aktiengesellschaft Dosieraerosole enthaltend den Wirkstoff D-18024 und verwandte Strukturen
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
JPH06135815A (ja) * 1992-10-30 1994-05-17 Shiseido Co Ltd 経皮吸収抑制組成物
ZA939195B (en) * 1992-12-09 1995-06-08 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
DE4321288A1 (de) * 1993-06-26 1995-01-05 Solvay Fluor & Derivate Zusammensetzungen mit chlorfreien, gegebenenfalls wasserstoffhaltigen Fluorkohlenwasserstoffen
WO1995015151A1 (en) * 1993-12-02 1995-06-08 Abbott Laboratories Aerosol drug formulations for use with non-cfc propellants
US5589156A (en) * 1994-05-02 1996-12-31 Henry; Richard A. Prilocaine and hydrofluourocarbon aerosol preparations
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
DE69530325T2 (de) * 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
JP3707107B2 (ja) * 1995-09-18 2005-10-19 鈴木油脂工業株式会社 薬剤分散液及びその製造方法
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6261472B1 (en) * 1996-11-04 2001-07-17 E. I. Du Pont De Nemours And Company Azeotrope-like compositions containing fluoroethane
US6361938B1 (en) * 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
AU725625B2 (en) * 1997-01-30 2000-10-19 Alpenstock Holdings Limited A composition
EP1014943B1 (de) * 1997-02-05 2002-06-19 Jago Research Ag Medizinische aerosolformulierungen
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
ATE283033T1 (de) * 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
BR0015884A (pt) * 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
DK2283818T3 (da) * 2000-11-30 2017-10-16 Vectura Ltd Fremgangsmåde til fremstilling af partikler til anvendelse i en farmaceutisk sammensætning
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
KR100947409B1 (ko) * 2002-03-01 2010-03-12 키에시 파르마슈티시 엣스. 피. 에이. 포모테롤 초미세 조성물
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations

Also Published As

Publication number Publication date
PT1372608E (pt) 2008-01-04
EP1372608B1 (de) 2007-10-10
NO20034323D0 (no) 2003-09-26
JP4824267B2 (ja) 2011-11-30
AU2002234476C1 (en) 2002-10-15
HU229798B1 (en) 2014-07-28
WO2002078671A1 (de) 2002-10-10
SK13342003A3 (sk) 2004-08-03
EP1372608A1 (de) 2004-01-02
HK1064295A1 (zh) 2005-01-28
CA2442415A1 (en) 2002-10-10
US20040101483A1 (en) 2004-05-27
CN100496608C (zh) 2009-06-10
CA2442415C (en) 2010-07-20
RO121172B1 (ro) 2007-01-30
NZ528640A (en) 2004-06-25
CZ301676B6 (cs) 2010-05-19
ATE375142T1 (de) 2007-10-15
CZ20032915A3 (en) 2004-06-16
NO332848B1 (no) 2013-01-21
AU2002234476B2 (en) 2006-04-27
NO20034323L (no) 2003-09-26
JP2004525148A (ja) 2004-08-19
SK286394B6 (sk) 2008-09-05
CY1107128T1 (el) 2012-10-24
PL362797A1 (en) 2004-11-02
ZA200307161B (en) 2005-01-26
ES2292713T3 (es) 2008-03-16
RU2003131676A (ru) 2005-02-10
RU2294737C2 (ru) 2007-03-10
CN1499958A (zh) 2004-05-26
PL207377B1 (pl) 2010-12-31
DE50211045D1 (de) 2007-11-22
HUP0401250A2 (hu) 2004-11-29
HUP0401250A3 (en) 2008-04-28

Similar Documents

Publication Publication Date Title
DK1372608T3 (da) Medicinske aerosolformuleringer
ATE373422T1 (de) Mikroemulsionbildende herbizidkonzentrate, mikroemulsionen und verfahren
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
DK1102579T3 (da) Medicinske aerosolformuleringer
DE60207198D1 (de) Transplantate für die wiederherstellung von osteochondralen schäden
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
BRPI0317696B8 (pt) composição para branqueamento
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
HUP0400520A2 (hu) Klindamicint és cinksót tartalmazó dermatológiai készítmények
BR0207725A (pt) Promotores do crescimento e/ou da diferenciação de células-tronco hematopoiéticas e/ou progenitores hematopoiéticos
UY27373A1 (es) Formulaciones de interferón beta-humano
ITMI20022549A1 (it) Composizione quaternaria comprendente come sostanza attiva la propolis.
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
ATE353642T1 (de) Verwendung von hypoestoxiden als antiparasitäre mittel
PL1868631T3 (pl) Zastosowanie związków indukujących syntezę białek SIRT przy lub dla otrzymywania kompozycji kosmetycznej lub farmaceutycznej
WO2004071386A3 (en) Compositions comprising microcapsules containing magnetic nanoparticles and biologically active molecules, their preparation and use
NO20080420L (no) Formulering med forlenget frigivelse av aktive bestanddeler med pH-avhengig loselighet
BRPI0410021A (pt) preparação farmacêutica sólida, que contém sais levotiroxina e/ou liotironina como substáncia ativa
EA200702386A1 (ru) Твердая фармацевтическая композиция для продолжительного высвобождения 1-(2,3,4-триметоксибензил)пиперазина и способ ее получения